Clinical Drug Investigation

, Volume 34, Issue 5, pp 309–316 | Cite as

Long-Term Efficacy of OROS® Hydromorphone Combined with Pregabalin for Chronic Non-Cancer Neuropathic Pain

  • Mario Dauri
  • Marzia Lazzari
  • Manuela Casali
  • Giuseppe Tufaro
  • Elisabetta Sabato
  • Alessandro Fabrizio Sabato
Original Research Article

Abstract

Background and Objectives

Treatment for chronic non-cancer neuropathic pain can be complicated by side effects and drug interactions. Combining opioid analgesics and calcium channel modulators may overcome these and improve efficacy. The objective of the present study was to evaluate the efficacy and safety of OROS® hydromorphone combined with pregabalin in patients with chronic non-cancer neuropathic pain.

Methods

This retrospective observational study was conducted on clinical records from patients aged ≥18 years with chronic non-cancer neuropathic [>4 on the Douleur Neuropathique en 4 questions (DN4) scale] pain of ≥6 months duration, with severe intensity [>4 on the Numerical Rating Scale (NRS); range 0–10], who attended all visits and had ≥12 months of follow-up at the Tor Vergata University Polyclinic Hospital, from November 2008 to February 2011. Patients received an oral combination of OROS® hydromorphone and pregabalin. Pain was evaluated at each visit (months 1, 3, 6, 9, and 12) using the NRS and DN4 scale; Patients’ Global Impression of Change (PGIC) was administered at months 1, 6, and 12. Dosage and side effects were recorded at each visit.

Results

Of 1,292 patients (32 % men, mean ± SD age 67.6 ± 11.9 years), 1,126 attended all visits. Seventeen percent (n = 224) had purely neuropathic pain. Initial mean dosage was 6.06 ± 2.00 mg/day for OROS® hydromorphone, 113.02 ± 21.94 mg/day for pregabalin. Dosages increased up to month 6, and returned to near initial dosages at month 12 (range 4–120 mg/day for OROS® hydromorphone; 75–600 mg/day for pregabalin). NRS pain scores (mean ± standard deviation) were 7.25 ± 1.34 at baseline and 1.85 ± 1.36 at 12 months (p < 0.0001); DN4 scores were 6.19 ± 1.65 at baseline, reduced to 1.84 ± 1.25 at 12 months (p < 0.0001), reductions of 74.4 and 70.2 %, respectively. More than 90 % of patients had a ≥50 % score reduction on both scales after 12 months. The PGIC scale showed that >75 % of patients felt improvement at 1 month, increasing to 91 % and 93 % at 6 and 12 months. The incidence of side effects was similar between elderly (aged >65 years) and younger subjects; there were no cases of addiction.

Conclusions

The OROS® hydromorphone and pregabalin combination was efficacious for chronic non-cancer neuropathic pain and well tolerated, providing significant pain reduction without the risk of addiction and with a good tolerability profile, regardless of age.

Notes

Acknowledgments

The study did not receive any funding. The authors have no conflicts of interest regarding the content of this article. The authors have full control of all primary data.

References

  1. 1.
    Gureje O, Von Korff M, Simon GE, et al. Persistent pain and well-being: a World Health Organization study in primary care. JAMA. 1998;280:147–51.PubMedCrossRefGoogle Scholar
  2. 2.
    Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin. 2011;27:449–62.PubMedCrossRefGoogle Scholar
  3. 3.
    Turk DC, Okifuji A. Pain terms and taxonomies of pain. In: Fishman SM, Ballantyne JC, Rathmell JP, editors. Bonica’s management of pain. 4th ed. New York: Lippincott Williams & Wilkins; 2009. p. 13–23.Google Scholar
  4. 4.
    Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Boogaard S, Heymans MW, Patijn J, et al. Predictors for persistent neuropathic pain: a Delphi survey. Pain Physician. 2011;14:559–68.PubMedGoogle Scholar
  6. 6.
    Tan T, Barry P, Reken S, et al. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ. 2010;340:c1079.PubMedCrossRefGoogle Scholar
  7. 7.
    Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e88.PubMedCrossRefGoogle Scholar
  8. 8.
    Namaka M, Gramlich CR, Ruhlen D, et al. A treatment algorithm for neuropathic pain. Clin Ther. 2004;26:951–79.PubMedCrossRefGoogle Scholar
  9. 9.
    Cruccu G. Treatment of painful neuropathy. Curr Opin Neurol. 2007;20:531–5.PubMedGoogle Scholar
  10. 10.
    Woolf CJ, American College of Physicians, American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140:441–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Romanò CL, Romanò D, Lacerenza M. Antineuropathic and antinociceptive drugs combination in patients with chronic low back pain: a systematic review. Pain Res Treat. 2012;2012:154781.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Gatti A, Sabato AF, Occhioni R, et al. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Eur Neurol. 2009;61:129–37.PubMedCrossRefGoogle Scholar
  13. 13.
    Gatti A, Longo G, Sabato E, et al. Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. Eur Neurol. 2011;65:317–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Matthews EA, Dickenson AH. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology. 2002;96:633–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Carter NJ, Keating GM. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain. CNS Drugs. 2010;24:337–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Sathyan G, Xu E, Thipphawong J, et al. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. BMC Clin Pharmacol. 2007;7:3.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Lussier D, Richarz U, Finco G. Use of hydromorphone, with particular reference to the OROS formulation, in the elderly. Drugs Aging. 2010;27:327–35.PubMedCrossRefGoogle Scholar
  19. 19.
    Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28:497–504.PubMedCrossRefGoogle Scholar
  20. 20.
    Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–51.PubMedCrossRefGoogle Scholar
  21. 21.
    Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29–36.PubMedCrossRefGoogle Scholar
  22. 22.
    Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–58.PubMedCrossRefGoogle Scholar
  23. 23.
    Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27:26–35.PubMedCrossRefGoogle Scholar
  24. 24.
    Zin CS, Nissen LM, O’Callaghan JP, et al. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain. 2010;11:462–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain. 2008;12:804–13.PubMedCrossRefGoogle Scholar
  26. 26.
    Concato J, Shah N, Horwitz R. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–92.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122:114–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Mario Dauri
    • 1
  • Marzia Lazzari
    • 1
  • Manuela Casali
    • 1
  • Giuseppe Tufaro
    • 1
  • Elisabetta Sabato
    • 2
  • Alessandro Fabrizio Sabato
    • 1
  1. 1.Department of Emergency and Admission, Critical Care Medicine, Pain Medicine and Anesthetic Science, Foundation PTV, Polyclinic Tor VergataUniversity of Rome “Tor Vergata”RomeItaly
  2. 2.Department of Emergency and Admission, Critical Care Medicine, Pain Medicine and Anesthetic SciencePolyclinic CasilinoRomeItaly

Personalised recommendations